カイノスの株価時系列
| 日付 | 始値 | 高値 | 安値 | 終値 | 前日比 | 騰落率 | 出来高 |
|---|---|---|---|---|---|---|---|
| 2025/01/21 | 1,284 | 1,284 | 1,284 | 1,284 | ±0 | ±0% | 1,200 |
| 2025/01/20 | 1,289 | 1,293 | 1,243 | 1,284 | +15 | +1.2% | 3,600 |
| 2025/01/17 | 1,271 | 1,271 | 1,242 | 1,269 | -4 | -0.3% | 3,800 |
| 2025/01/16 | 1,250 | 1,273 | 1,250 | 1,273 | +23 | +1.8% | 2,200 |
| 2025/01/15 | 1,242 | 1,263 | 1,242 | 1,250 | -2 | -0.2% | 2,000 |
| 2025/01/14 | 1,305 | 1,305 | 1,246 | 1,252 | -67 | -5.1% | 7,100 |
| 2025/01/10 | 1,266 | 1,321 | 1,256 | 1,319 | +58 | +4.6% | 33,000 |
| 2025/01/09 | 1,243 | 1,262 | 1,241 | 1,261 | +18 | +1.4% | 7,700 |
| 2025/01/08 | 1,240 | 1,252 | 1,240 | 1,243 | +2 | +0.2% | 2,100 |
| 2025/01/07 | 1,230 | 1,265 | 1,229 | 1,241 | +11 | +0.9% | 21,500 |
| 2025/01/06 | 1,237 | 1,239 | 1,230 | 1,230 | -6 | -0.5% | 1,100 |
| 2024/12/30 | 1,219 | 1,236 | 1,219 | 1,236 | +8 | +0.7% | 2,100 |
| 2024/12/27 | 1,211 | 1,228 | 1,207 | 1,228 | +17 | +1.4% | 500 |
| 2024/12/26 | 1,212 | 1,212 | 1,204 | 1,211 | +1 | +0.1% | 1,000 |
| 2024/12/25 | 1,231 | 1,231 | 1,196 | 1,210 | -21 | -1.7% | 2,600 |
| 2024/12/24 | 1,231 | 1,231 | 1,224 | 1,231 | -8 | -0.6% | 1,200 |
| 2024/12/23 | 1,240 | 1,241 | 1,233 | 1,239 | -3 | -0.2% | 1,800 |
| 2024/12/20 | 1,241 | 1,242 | 1,238 | 1,242 | +4 | +0.3% | 1,400 |
| 2024/12/19 | 1,229 | 1,238 | 1,222 | 1,238 | +9 | +0.7% | 1,500 |
| 2024/12/18 | 1,238 | 1,238 | 1,207 | 1,229 | -15 | -1.2% | 2,100 |
| 2024/12/17 | 1,244 | 1,245 | 1,231 | 1,244 | ±0 | ±0% | 2,000 |
| 2024/12/16 | 1,238 | 1,244 | 1,230 | 1,244 | +4 | +0.3% | 2,600 |
| 2024/12/13 | 1,230 | 1,244 | 1,229 | 1,240 | +7 | +0.6% | 3,100 |
| 2024/12/12 | 1,222 | 1,233 | 1,221 | 1,233 | +9 | +0.7% | 1,200 |
| 2024/12/11 | 1,225 | 1,234 | 1,221 | 1,224 | +3 | +0.2% | 6,200 |
| 2024/12/10 | 1,228 | 1,228 | 1,221 | 1,221 | +1 | +0.1% | 400 |
| 2024/12/09 | 1,218 | 1,232 | 1,213 | 1,220 | +8 | +0.7% | 3,000 |
| 2024/12/06 | 1,227 | 1,228 | 1,210 | 1,212 | -13 | -1.1% | 1,700 |
| 2024/12/05 | 1,200 | 1,229 | 1,200 | 1,225 | +1 | +0.1% | 1,400 |
| 2024/12/04 | 1,225 | 1,225 | 1,202 | 1,224 | +4 | +0.3% | 700 |
| 2024/12/03 | 1,228 | 1,228 | 1,215 | 1,220 | -9 | -0.7% | 1,000 |
| 2024/12/02 | 1,224 | 1,229 | 1,223 | 1,229 | +6 | +0.5% | 700 |
| 2024/11/29 | 1,223 | 1,223 | 1,220 | 1,223 | +5 | +0.4% | 300 |
| 2024/11/28 | 1,200 | 1,220 | 1,200 | 1,218 | -7 | -0.6% | 1,300 |
| 2024/11/27 | 1,223 | 1,225 | 1,220 | 1,225 | +6 | +0.5% | 1,500 |
| 2024/11/26 | 1,205 | 1,227 | 1,205 | 1,219 | -9 | -0.7% | 1,200 |
| 2024/11/25 | 1,200 | 1,236 | 1,200 | 1,228 | +28 | +2.3% | 1,400 |
| 2024/11/22 | 1,209 | 1,209 | 1,192 | 1,200 | -3 | -0.2% | 1,200 |
| 2024/11/21 | 1,206 | 1,226 | 1,201 | 1,203 | -27 | -2.2% | 2,200 |
| 2024/11/20 | 1,231 | 1,237 | 1,230 | 1,230 | -1 | -0.1% | 1,800 |
| 2024/11/19 | 1,207 | 1,231 | 1,188 | 1,231 | +23 | +1.9% | 5,800 |
| 2024/11/18 | 1,177 | 1,212 | 1,177 | 1,208 | +13 | +1.1% | 3,000 |
| 2024/11/15 | 1,210 | 1,210 | 1,183 | 1,195 | -17 | -1.4% | 1,200 |
| 2024/11/14 | 1,214 | 1,214 | 1,181 | 1,212 | -1 | -0.1% | 2,600 |
| 2024/11/13 | 1,214 | 1,214 | 1,200 | 1,213 | -3 | -0.2% | 1,500 |
| 2024/11/12 | 1,214 | 1,219 | 1,199 | 1,216 | +2 | +0.2% | 3,300 |
| 2024/11/11 | 1,174 | 1,220 | 1,174 | 1,214 | +40 | +3.4% | 5,900 |
| 2024/11/08 | 1,191 | 1,192 | 1,174 | 1,174 | -16 | -1.3% | 900 |
| 2024/11/07 | 1,161 | 1,190 | 1,161 | 1,190 | -1 | -0.1% | 1,500 |
| 2024/11/06 | 1,186 | 1,196 | 1,161 | 1,191 | +21 | +1.8% | 2,100 |
51～
100
件表示中 / 3673件
類似銘柄と比較する
現在ご覧いただいている「カイノス」と類似性の高い銘柄をピックアップ。投資家が注目しているデータで比較できるようになっています。銘柄選びの参考情報としてご活用ください。
| 銘柄名 | 最低購入代金 | 売上高 成長率 |
経常 増益率 |
配当 利回り |
PER | PBR | 直近のチャート | 特色 |
|---|---|---|---|---|---|---|---|---|
| カイノス | 118,400円 | +6.8% | -13.8% | 2.96% | 9.07倍 | 0.77倍 |
|
臨床検査薬の中堅メーカー。生化学、免疫血清学的検査用試薬に重点。共同開発の促進に注力 |
| モダリス | 7,800円 | - | - | 0.00% | - | 1.63倍 |
|
遺伝子治療薬の創薬ベンチャー、ＤＮＡ切断しないエピゲノム編集に強み。研究開発中心は米国 |
| ティムス | 14,200円 | - | - | 0.00% | - | 1.93倍 |
|
東京農工大発創薬ベンチャー。黒カビ由来の急性期脳梗塞薬候補を中国ＣＯＲＸＥＬ社に導出 |
| クリングル | 78,700円 | +240.0% | - | 0.00% | - | 2.58倍 |
|
細胞の増殖、保護、修復などの機能があるＨＧＦタンパク質を用いて、難治性疾患治療薬を開発 |
| カルナバイオ | 25,900円 | +13.5% | - | 0.00% | - | 2.00倍 |
|
キナーゼタンパク質の販売や受託試験など創薬初期の支援事業が柱。キナーゼ阻害剤で創薬も |
市場注目の銘柄
チャート関連のコラム
